Seroatlas · Human Serome Atlas

GARIN5A

Golgi-associated RAB2 interactor protein 5A

Also known as: FAM71E1, GAR5A_HUMAN, GARIL5

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6IPT2
Gene: GARIN5A
Ensembl: ENSG00000142530
Chromosome: 19
Canonical length: 247 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoli fibrillar center

OverviewNCBI Gene

Predicted to be involved in defense response to virus; innate immune response; and positive regulation of type I interferon production. Predicted to act upstream of or within several processes, including flagellated sperm motility; penetration of zona pellucida; and spermatid development. Predicted to be located in Golgi apparatus. Predicted to be active in sperm head. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

247 residues, UniProt reviewed canonical sequence.

>Q6IPT2|GARIN5A
     1  MGPPLWPDLQ EPPPPGTSSQ IRSPLLCDVI KPAPHHDVTV RVVPPPRFLP LLLRPLPSDG
    61  DIAMRRDRGP KPALGGAGEV EPGGMAASPT GRPRRLQRYL QSGEFDQFRD FPIFESNFVQ
   121  FCPDIYPAPT SDLWPQVTRL GEVANEVTMG VAASSPALEL PDLLLLAGPA KENGHLQLFG
   181  LFPLKFVQLF VHDKSRCQLE VKLNTSRTFY LQLRAPLKTR DREFGQWVRL LYRLRFLSAS
   241  AVPFTQE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GARIN5A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.43
Highest tissue expression: 68 nTPM

Expression across tissuesHPA

Tissue

testis: 68 nTPM
basal ganglia: 8.4 nTPM
hypothalamus: 8.4 nTPM
midbrain: 8.2 nTPM
cerebral cortex: 7.7 nTPM
amygdala: 7.3 nTPM

Single-cell type

late spermatids: 4,823 nCPM
early spermatids: 2,396 nCPM
late primary spermatocytes: 632 nCPM
oocytes: 106 nCPM
cardiomyocytes: 37 nCPM
undifferentiated spermatogonia: 29 nCPM

Immune cell

NK-cell: 1.5 nTPM
MAIT T-cell: 1.2 nTPM
naive B-cell: 1.1 nTPM
naive CD8 T-cell: 1 nTPM
eosinophil: 0.9 nTPM
naive CD4 T-cell: 0.9 nTPM

Brain region

cerebellum: 11 nTPM
medulla oblongata: 8.7 nTPM
hypothalamus: 7.6 nTPM
pons: 6.8 nTPM
basal ganglia: 5.9 nTPM
cerebral cortex: 5.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.58
gnomAD pLI: 0
DepMap mean gene effect: 0.07
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Golgi apparatus

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Golgi apparatus

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GARIN5A as an antibody target. Whether an autoantibody or antibody against GARIN5A could matter depends on whether native GARIN5A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GARIN5A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label GARIN5A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...